This activity has expired. Credit is no longer available.
This activity is supported by educational grants provided by Amgen, AstraZeneca, Celgene Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., Takeda Oncology, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Emerging Therapies for Multiple Myeloma
Patrick J. Kiel, PharmD, BCPS, BCOP
IU Simon Cancer Center
The overall survival of patients with multiple myeloma has increased within the past decade, thanks to newer agents such as immunomodulatory drugs and proteasome inhibitors. Receive updated data on key FDA approvals and practice updates for maximizing therapies while mitigating adverse events.
|
|
These activities, certified for CME/CE/CPE credit, are jointly provided by
  |